$2.53
-0.02-0.78%
Last update: Nov 6, 12:32 PM
Editas Medicine Inc (EDIT) Stock Price, Quote, News & History
EDITNASDAQ
Editas Medicine pivots to in vivo gene editing, extends cash runway to 2027, but faces investor caution amid unclear proof-of-concept timelines.
You can purchase shares of Editas Medicine (NASDAQ:EDIT) through any online brokerage.
Other companies in Editas Medicine’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Editas Medicine has a consensus price target of $6.76.
The stock price for Editas Medicine (NASDAQ: EDIT) is $2.53 last updated November 6, 2026 at 12:32 PM EST.
There are no upcoming dividends for Editas Medicine.
Editas Medicine does not have any upcoming earnings scheduled.
There is no upcoming split for Editas Medicine.
Editas Medicine is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform...
